Bone marrow chimeric mice reveal a dual role for CD36 in Plasmodium berghei ANKA infection by Cunha-Rodrigues, M. et al.
BioMed CentralMalaria Journal
ssOpen AcceResearch
Bone marrow chimeric mice reveal a dual role for CD36 in 
Plasmodium berghei ANKA infection
Margarida Cunha-Rodrigues1,2, Sílvia Portugal1,2, Maria Febbraio3 and 
Maria M Mota*1,2
Address: 1Unidade de Malária, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-
028 Lisboa, Portugal, 2Instituto Gulbenkian de Ciência, 2781-156 Oeiras, Portugal and 3Cell Biology, Lerner Research Institute, Cleveland Clinic, 
Cleveland, Ohio, USA
Email: Margarida Cunha-Rodrigues - margaridacunha@fm.ul.pt; Sílvia Portugal - sportugal@fm.ul.pt; Maria Febbraio - febbram@ccf.org; 
Maria M Mota* - mmota@fm.ul.pt
* Corresponding author    
Abstract
Background: Adhesion of Plasmodium-infected red blood cells (iRBC) to different host cells,
ranging from endothelial to red blood cells, is associated to malaria pathology. In vitro studies have
shown the relevance of CD36 for adhesion phenotypes of Plasmodium falciparum iRBC such as
sequestration, platelet mediated clumping and non-opsonic uptake of iRBC. Different adhesion
phenotypes involve different host cells and are associated with different pathological outcomes of
disease. Studies with different human populations with CD36 polymorphisms failed to attribute a
clear role to CD36 expression in human malaria. Up to the present, no in vivo model has been
available to study the relevance of different CD36 adhesion phenotypes to the pathological course
of Plasmodium infection.
Methods: Using CD36-deficient mice and their control littermates, CD36 bone marrow chimeric
mice, expressing CD36 exclusively in haematopoietic cells or in non-haematopoietic cells, were
generated. Irradiated CD36-/- and wild type mice were also reconstituted with syngeneic cells to
control for the effects of irradiation. The reconstituted mice were infected with Plasmodium berghei
ANKA and analysed for the development of blood parasitaemia and neurological symptoms.
Results: All mice reconstituted with syngeneic bone marrow cells as well as chimeric mice
expressing CD36 exclusively in non-haematopoietic cells died from experimental cerebral malaria
between day 6 and 12 after infection. A significant proportion of chimeric mice expressing CD36
only in haematopoietic cells did not die from cerebral malaria.
Conclusion: The analysis of bone marrow chimeric mice reveals a dual role of CD36 in P. berghei
ANKA infection. Expression of CD36 in haematopoietic cells, most likely macrophages and dendritic
cells, has a beneficial effect that is masked in normal mice by adverse effects of CD36 expression
in non-haematopoietic cells, most likely endothelial cells.
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Malaria is the consequence of Plasmodium infection that
occurs in a variety of forms, affecting many organs, with
different pathological and clinical features [1]. The mech-
anisms behind the pathogenesis of the various disease
syndromes remain poorly understood. The interactions of
infected red blood cells (iRBC) with various cells of the
host (often referred to as adhesion phenotypes) are
thought to be involved in several features of the disease.
The accumulation of iRBC in the microvasculature of var-
ious organs is believed to protect the parasite from elimi-
nation by the spleen and to be a prominent cause of
organ-specific malaria syndromes [2]. Non-opsonic
phagocytosis is thought to eliminate parasites in a non-
inflammatory manner that is reminiscent of the removal
of apoptototic cells [3-8]. Several host cells that are
involved in iRBC adhesion phenotypes are also involved
in general inflammation processes and immune
responses of the host. CD36 is a multiligand scavenger
receptor that is expressed by many of these cells such as
endothelial cells, platelets, dendritic cells and macro-
phages [9], as well as on both erythroid precursors [10]
and normal erythrocytes [11,12]. Adhesion phenotypes
involving CD36 include iRBC binding to endothelial cells
[13,14] and platelet mediated clumping [15], both of
which contribute to the occlusion of the microvasculature
in target organs. Non-opsonic uptake of iRBC contributes
to the clearance of parasites and modulation of phago-
cytic cells [3-8]. Thus, CD36 is involved in a variety of
host-parasite interactions that may be protective and
harmful to both the host and the parasite (reviewed in
[8]). Moreover, studies attempting to associate severe
malaria syndromes with CD36 polymorphisms in human
populations have yielded conflicting results [16-18].
Thus, the role of CD36 in the pathology of human malaria
remains elusive and CD36-mediated adhesion cannot be
considered as a validated target for anti-malarial interven-
tion.
In the present work, CD36 bone marrow chimeric mice
were generated to dissect and measure the contribution of
CD36 expression by resident cells versus its role in circulat-
ing cells to disease outcome. The exclusive expression of
CD36 in haematopoietic cells resulted in 25% protection
from experimental cerebral malaria (ECM). In wild type
mice this protective effect appears to be counteracted by
CD36 expression in non-haematopoietic cells. These
results indicate that, to be effective, agents that target
CD36-binding for malaria intervention need to be cell-
type specific, a requirement that cannot readily be met by
present day technologies of drug development.
Methods
Mice, parasites and infection
Seven to nine-week old male CD36-deficient mice
(C57Bl/6 background) [19] and their wild type littermates
were infected with fresh 106 green fluorescent protein
(GFP)-expressing Plasmodium berghei ANKA iRBCs [20] by
intra-peritoneal (i.p.) injection, after one passage through
mice infected from a frozen vial. Peripheral blood parasi-
taemia was determined by flow cytometry and expressed
as percentage of infected red blood cells, as described else-
where [20]. Mice were observed for cerebral complica-
tions, i.e ataxia, paralysis, deviation of the head and
convulsions, coma and death.
CD36 bone marrow chimeric mice
CD36-/- mice were lethally γ-irradiated (900 rads) and
reconstituted with CD36+/+ bone marrow cells (CD36+/+
into CD36-/- chimeras) or CD36-/- bone marrow cells
(CD36-/- into CD36+/+). Reverse chimeric mice were also
created by lethally irradiating CD36+/+ mice and reconsti-
tuting them with either CD36-/- (CD36-/- into CD36+/+ chi-
meras) or CD36+/+ bone marrow cells (CD36+/+ into
CD36+/+ chimeras). Bone marrow cells from donor mice
(6.5 × 106) were injected into each recipient mouse
through the retro-orbital venous plexus one to five hours
after irradiation. Chimeric animals were allowed to
recover for five weeks before infection was initiated as
described above. Depletion of circulating cells and recon-
stitution with donor cells was confirmed in all chimeric
mice by PCR of blood genomic DNA. Blood was collected
from the tail and DNA extracted using QIAamp DNA
Micro Kit (Qiagen). PCR was performed using PCR Master
Mix (Promega kit) and a set of three primers that amplify
sequence either from the wild type (600 bp) or knockout
(750–800 bp) allele. The following oligonucleotides (5'-
3') were used for specific amplification: CAGCTCATA-
CATTGCTGTTTATGCATG, GGTACAATCACAGTGTTTTC-
TACGTGG and CCGCTTCCTCGT GCTTTACGGTATC.
Amplification program: 95° 4 min-1 cycle; 94° 1 min,
65° 1 min, 72° 2 min- 30 cycles; 4° ∞.
Results and discussion
CD36 is expressed by both haematopoietic and non-hae-
matopoietic cells [9-12]. CD36 is not only an important
mediator of microvessels obstruction by Plasmodium falci-
parum iRBC, but also required for the non-opsonic phago-
cytosis of different stages of P. falciparum iRBC
[4,5,21,22]. No consensus has been reached regarding the
role of CD36 in the development of severe malaria syn-
dromes in humans [8,23]. Since rodent malaria iRBCs
also bind CD36 [24,25], mouse models may be used to
study the requirement of CD36 in various features of Plas-
modium infection [26]. Like in humans, Plasmodium infec-
tion of mice results in different pathologies that depend
on the genomes of both the parasite and the host [26,27].Page 2 of 5
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accumulation of P. berghei ANKA iRBC in the lungs and
adipose tissues, but has no role in the development of par-
asitaemia and the lethal course of ECM [25].
To further define the role of CD36 expression in circulat-
ing cells such as macrophages and DCs, CD36 chimeric
mice were generated by bone marrow transplantation. To
control for irradiation effects CD36-/- mice and wild-type
mice were also reconstituted with syngeneic bone marrow
cells. Five weeks after reconstitution, chimeras showed
more than 90% chimerism, as determined by blood
genomic DNA PCR (data not shown). The four groups of
reconstituted mice were then infected with P. berghei
Bone marrow chimeric mice with CD36 expression confined to lethal radiation-sensitive cells are partially protected from CMFigure 1
Bone marrow chimeric mice with CD36 expression confined to lethal radiation-sensitive cells are partially pro-
tected from CM. (A) Cumulative survival and parasitaemias (C) of CD36+/+ into CD36+/+ (n = 11) and CD36-/- into CD36+/+ 
(n = 11) through the course of P. berghei ANKA infection. (B) Cumulative survival and parasitaemias (D) of CD36+/+ into CD36-
/- (n = 31) and CD36-/- into CD36-/- (n = 18) through the course of P. berghei ANKA infection. Survival curves represent the 
summary of four of independent experiments. Parasitaemia curves are from one representative experiment out of the four 
performed. In two independent experiments, CD36+/+bmCD36-/- and CD36-/-bmCD36+/+ were generated and infected at same 
time. LOG-RANK Test: P < .001 for curve (B). ●  CD36+/+ into CD36+/+, ❍ CD36-/- into CD36+/+,  CD36-/- into CD36-/-, ? 
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background. The two groups of mice reconstituted with
syngeneic bone marrow cells (Figure 1A and 1B) and
CD36-/- into CD36+/+ chimeras (Figure 1A) died six to 12
days after infection with neurological symptoms like pre-
viously observed for non-irradiated CD36-/- and wild type
C57BL/6 mice. However, a significant proportion (25.8 ±
9.3 %, n = 31) of chimeras expressing CD36 exclusively in
haematopoietic cells, but not in other cells (CD36+/+ into
CD36-/- chimeras) did not develop ECM (Figure 1B).
These mice survived ECM and died later with higher para-
sitaemias (Figure 1D). No differences were observed
between each chimeric group and its syngenic control in
the development of peripheral blood parasitaemia (Figure
1C and 1D). These findings suggest a small, but significant
beneficial role for CD36 when expressed only in haemat-
opoietic cells and an adverse effect when expressed else-
where.
CD36-mediated adhesion phenotypes involving haemat-
opoietic cells include non-opsonic phagoytosis of iRBC by
macrophages and dendritic cells and platelet mediated
clumping. The later contributes to the obstruction of the
microvasculature [15,28] and thus it is unlikely to be
responsible for the beneficial effect of CD36 expression in
haematopoietic cells that is apparent in the CD36+/+ into
CD36-/- chimeras. Whether additional abrogation of
CD36 expression in platelets of CD36+/+ into CD36-/- chi-
meras would lead to a higher protection still remains to be
elucidated.
The present study provides the first in vivo evidence, albeit
indirect, that non-opsonic phagocytosis of iRBC by mac-
rophages and dendritic cells may have a beneficial effect
in malaria infections and reduce the risk of development
of ECM. In non-chimeric animals, as it might be in
humans, this beneficial effect of CD36 is apparently off-
set, by adverse effects of CD36 expression in non-haemat-
opoietic cells, such as endothelial cells. Our results suggest
that therapeutic effects could only be achieved by either
up-regulating CD36 expression in macrophages and den-
dritic cells and/or by downregulating CD36 expression by
endothelial cells. A recent study has shown that CD36
expression and phagocytosis of iRBC could be selectively
up-regulated by agonists of the peroxisome proliferator
activated receptor γ (PPARγ) such as troglitazone [29].
Such selective up-regulation of CD36 in macrophages and
dendritic cells may shift the balance towards the benefi-
cial effects of CD36. However, this approach is not likely
to have a significant effect in endemic areas where the
populations have developed anti-Plasmodium antibodies
and are thus less dependent on non-opsonic phagocyto-
sis.
Conclusion
Although clear differences between malaria infections in
humans and mice exist, certain aspects of the infection are
comparable [26]. CD36 expression and CD36-mediated
adhesion of iRBCs to the microvasculature, for example,
has been shown not only for P. falciparum, but also for the
rodent parasites Plasmodium chabaudi [24] and P. berghei
[25]. Studies on human populations polymorphisms for
CD36 failed to define a clear role for CD36 in severe
malaria syndromes [16-18]. The present study with bone
marrow chimeric mice revealed both beneficial and
adverse effects of CD36 in infections with P. berghei
ANKA. Taken together with observations in humans, this
study in mice indicates that CD36 is not a straightforward
anti-malarial drug target and does not support further
efforts to develop drugs that indiscriminately block all
CD36 functions.
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